Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2015, Article ID 198343, 9 pages
http://dx.doi.org/10.1155/2015/198343
Research Article

Noninterventional Study of Transdermal Fentanyl (Fentavera) Matrix Patches in Chronic Pain Patients: Analgesic and Quality of Life Effects

1Faculty of Biology, University of Freiburg, Schänzlestraße 1, 79104 Freiburg, Germany
2MSL Consulting, Lujo Brentanos Strasse 11a, 83209 Prien, Germany

Received 5 January 2015; Revised 25 February 2015; Accepted 2 March 2015

Academic Editor: Robert L. Barkin

Copyright © 2015 Manuel Heim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Anon, Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, Edited by C. Committee on Advancing Pain Research, and Education; Institute of Medicine, National Research (USA), The National Academies Press, 2011.
  2. H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, “Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment,” European Journal of Pain, vol. 10, no. 4, pp. 287–333, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Tsang, M. von Korff, S. Lee et al., “Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders,” Journal of Pain, vol. 9, no. 10, pp. 883–891, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. WHO, Cancer Pain Relief. With a Guide to Opioid Availability, World Health Organization, Geneva, Switzerland, 2nd edition, 1996.
  5. P. G. Fine, C. Miaskowski, and J. A. Paice, “Meeting the challenges in cancer pain management,” Journal of Supportive Oncology, vol. 2, no. 6, supplement 4, pp. 5–22, 2004. View at Google Scholar · View at Scopus
  6. H. G. Kress, “Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine,” European Journal of Pain, vol. 13, no. 3, pp. 219–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. K. Portenoy, J. T. Farrar, M.-M. Backonja et al., “Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study,” Clinical Journal of Pain, vol. 23, no. 4, pp. 287–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. L. J. Lehmann, J. M. Desio, and T. Radvany, “Transdermal fentanyl in postoperative pain,” Regional Anesthesia, vol. 22, no. 1, pp. 24–28, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. WHO, Cancer Pain Relief, 1996.
  10. WHO, 2014, http://www.who.int/cancer/palliative/painladder/en/.
  11. R. Chou, G. J. Fanciullo, P. G. Fine et al., “Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain,” Journal of Pain, vol. 10, no. 2, pp. 113.e22–130.e22, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Johnson, B. Collett, and J. M. Castro-Lopes, “The challenges of pain management in primary care: a pan-European survey,” Journal of Pain Research, vol. 6, pp. 393–401, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. WHO, WHO Guidelines on the Pharmacological Treatment of Persisting Pain in Children with Medical Illnesses, World Health Organisation, Geneva, Switzerland, 2012.
  14. L. Nelson and R. Schwaner, “Transdermal fentanyl: pharmacology and toxicology,” Journal of Medical Toxicology, vol. 5, no. 4, pp. 230–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. D. Roy and G. L. Flynn, “Transdermal delivery of narcotic analgesics: comparative permeabilities of narcotic analgesics through human cadaver skin,” Pharmaceutical Research, vol. 6, no. 10, pp. 825–832, 1989. View at Publisher · View at Google Scholar · View at Scopus
  16. R. B. R. Muijsers and A. J. Wagstaff, “Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control,” Drugs, vol. 61, no. 15, pp. 2289–2307, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. T. L. Skaer, “Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain,” Journal of Pain Research, vol. 7, pp. 495–503, 2014. View at Publisher · View at Google Scholar
  18. A. J. Clark, S. H. Ahmedzai, L. G. Allan et al., “Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain,” Current Medical Research and Opinion, vol. 20, no. 9, pp. 1419–1428, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Zernikow, E. Michel, and B. Anderson, “Transdermal fentanyl in childhood and adolescence: a comprehensive literature review,” The Journal of Pain, vol. 8, no. 3, pp. 187–207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Menten, M. Desmedt, D. Lossignol, and A. Mullie, “Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients,” Current Medical Research and Opinion, vol. 18, no. 8, pp. 488–498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Milligan, M. Lanteri-Minet, K. Borchert et al., “Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain,” Journal of Pain, vol. 2, no. 4, pp. 197–204, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Donner, M. Zenz, M. Strumpf, and M. Raber, “Long-term treatment of cancer pain with transdermal fentanyl,” Journal of Pain and Symptom Management, vol. 15, no. 3, pp. 168–175, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Allan, H. Hays, N. H. Jensen et al., “Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain,” British Medical Journal, vol. 322, no. 7295, pp. 1154–1158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. R. K. Portenoy, J. Messina, F. Xie, and J. Peppin, “Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study,” Current Medical Research and Opinion, vol. 23, no. 1, pp. 223–233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Rhiner, G. Palos, and M. Termini, “Managing breakthrough pain: a clinical review with three case studies using oral transmucosal fentanyl citrate,” Clinical Journal of Oncology Nursing, vol. 8, no. 5, pp. 507–512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. FDA, Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Edited by United States Department of Health and Human Services Food and Drug Administration, FDA, 2009.
  27. D. C. Turk and M. J. M. Cohen, “Sleep as a marker in the effective management of chronic osteoarthritis pain with opioid analgesics,” Seminars in Arthritis and Rheumatism, vol. 39, no. 6, pp. 477–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. D. C. Turk, R. H. Dworkin, D. Revicki et al., “Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain,” Pain, vol. 137, no. 2, pp. 276–285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Foster, D. Hunter, and S. Samman, “Evaluation of the nutritional and metabolic effects of aloe vera,” in Herbal Medicine: Biomolecular and Clinical Aspects, I. Benzie and S. Wachtel-Galor, Eds., chapter 3, CRC Press, Boca Raton, Fla, USA, 2011. View at Google Scholar
  30. S. E. Dal'Belo, L. Rigo Gaspar, and P. M. B. G. Maia Campos, “Moisturizing effect of cosmetic formulations containing Aloe vera extract in different concentrations assessed by skin bioengineering techniques,” Skin Research and Technology, vol. 12, no. 4, pp. 241–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. BMJV, Gesetz über den Verkehr mit Arzneimitteln (Arzneimittelgesetz—AMG), BGBl. I S. 3394, Bundesministerium der Justiz und Verbraucherschutz, Berlin, Germany, 2005.
  32. Fentavera SmPC, “Summary of medicinal product characteristics of Fentavera, UK,” 2011.
  33. J. T. Farrar, J. P. Young Jr., L. LaMoreaux, J. L. Werth, and R. M. Poole, “Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale,” Pain, vol. 94, no. 2, pp. 149–158, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Radbruch, R. Sabatowski, F. Petzke, A. Brunsch-Radbruch, S. Grond, and K. A. Lehmann, “Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients,” Palliative Medicine, vol. 15, no. 4, pp. 309–321, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Zimmermann and I. Waap, “Individual aspects of the quality of life of patients with chronic pain. Observational study of treatment with fentanyl-TTS,” MMW-Fortschritte der Medizin, vol. 147, supplement 1, pp. 33–40, 2005. View at Google Scholar · View at Scopus
  36. J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Drewes, K. D. Nielsen, L. Arendt-Nielsen, L. Birket-Smith, and L. M. Hansen, “The effect of cutaneous and deep pain on the electroencephalogram during sleep an experimental study,” Sleep, vol. 20, no. 8, pp. 632–640, 1997. View at Google Scholar · View at Scopus
  38. Y. H. Chiu, A. J. Silman, G. J. Macfarlane et al., “Poor sleep and depression are independently associated with a reduced pain threshold. Results of a population based study,” Pain, vol. 115, no. 3, pp. 316–321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Gatti, G. Longo, E. Sabato, and A. F. Sabato, “Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study,” European Neurology, vol. 65, no. 6, pp. 317–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. U. Schutter, S. Grunert, C. Meyer, T. Schmidt, and T. Nolte, “Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice,” Current Medical Research and Opinion, vol. 26, no. 6, pp. 1377–1387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Varrassi and G. H. H. Müller-Schwefe, “The international CHANGE PAIN physician survey: does specialism influence the perception of pain and its treatment?” Current Medical Research and Opinion, vol. 28, no. 5, pp. 823–831, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. D. F. Cella, “Measuring quality of life in palliative care,” Seminars in Oncology, vol. 22, supplement 3, pp. 73–81, 1995. View at Google Scholar · View at Scopus
  43. H. Knotkova, P. G. Fine, and R. K. Portenoy, “Opioid rotation: the science and the limitations of the equianalgesic dose table,” Journal of Pain and Symptom Management, vol. 38, no. 3, pp. 426–439, 2009. View at Publisher · View at Google Scholar · View at Scopus